{
    "2019-08-04": [
        [
            {
                "time": "",
                "original_text": "【国元医药】四联苗全年销售可期，后续产品线丰富——康泰生物2019H1点评",
                "features": {
                    "keywords": [
                        "四联苗",
                        "全年销售",
                        "产品线",
                        "康泰生物"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【西南医药|2019中报点评】康泰生物（300601）：业绩符合预期，下半年有望恢复高增长",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "业绩",
                        "中报",
                        "高增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}